Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806611 · ClinicalTrials.gov registry record · Phase 3
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
A Phase 3 study of Pancreatic Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 3
- Development phase
- 438
- Enrollment target
- 1
- Study location
NCT00806611 is a Phase 3 study of Pancreatic Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 438 participants, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00806611, a Phase 3 study of Pancreatic Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 438 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine if the addition of an intraoperative ethanol celiac plexus neurolysis (alcohol block) in patients undergoing surgical intervention for pancreatic cancer will result in a decrease in cancer associated pain
Conditions Studied
Interventions
- PROCEDURE Alcohol Block
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806611
The ClinicalTrials.gov registry entry for NCT00806611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (12% higher). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Alcohol Block is the first listed.
NCT00806611 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00806611 about?
NCT00806611 is a clinical study titled "Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer". Determine if the addition of an intraoperative ethanol celiac plexus neurolysis (alcohol block) in patients undergoing surgical intervention for pancreatic cancer will result in a decrease in cancer associated pain
What is the current status of trial NCT00806611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 438 participants. The study started on 2008-09. Estimated completion is 2013-04.
What conditions does trial NCT00806611 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00806611?
The interventions under investigation include: Alcohol Block (PROCEDURE).
Who is sponsoring clinical trial NCT00806611?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00806611 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.